Abiopharma

I-Mab reports latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab. Uliled Limab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity. Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort. Results indicate CD73 expression correlates with clinical response as a potential predictive biomarker. Company aims to initiate Phase 3 study in NSCLC in 2023.